)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Immunovia (IMMNOV) investor relations material
Immunovia Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary28 Aug, 2025
Executive summary
PancreaSure, a blood-based test for early pancreatic cancer detection, is set for commercial launch in September 2025, with strong endorsements from key opinion leaders and initial adoption by seven leading US surveillance centers.
Achieved significant scientific recognition, including Best of DDW and Distinguished Abstract Award for clinical and analytical validation studies.
Focused on targeted advocacy, phased market entry, and operational efficiencies, with management leading initial sales efforts and no sales reps hired yet.
Secured a CPT/AMA code for PancreaSure, enabling insurance claims submission and supporting reimbursement efforts.
Key hires made to support market access and reimbursement, with ongoing collaborations and NIH-funded studies to expand the evidence base.
Financial highlights
Operating expenses for Q2 2025 were SEK 20 million, a 17% reduction year-over-year.
Cash balance at the end of Q2 2025 was SEK 29.3 million, better than projected.
Monthly cash burn reduced to SEK 6 million in Q2, below the projected SEK 8–10 million, but expected to rise with commercialization.
Net loss for Q2 2025 was SEK -41.1 million, impacted by unrealized currency effects.
Net sales for Q2 2025 were SEK 90 thousand, consisting solely of royalties.
Outlook and guidance
Rights issue announced to raise up to SEK 100 million, 80% guaranteed, to fund commercialization and clinical studies, with strong insider and board participation.
Capital expected to support operations well into 2026 if fully subscribed, with a focus on non-dilutive funding for future needs.
Commercial strategy involves a phased launch, initially targeting high-risk centers and key opinion leaders, expanding to broader physician groups and revenue growth by 2027.
Medicare reimbursement for PancreaSure is anticipated in the second half of 2025, with a reimbursement application planned for the first half of 2026.
Cash burn is expected to increase as commercialization and clinical studies ramp up.
PancreaSure initial market adoption plan
Medicare reimbursement: next key milestones
What is the status of the old lease contract?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Immunovia earnings date
Q3 202519 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Immunovia AB, a Swedish diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company was founded in 2007 and is listed on Nasdaq Stockholm First North Premier under the ticker IMMUV. Immunovia focuses on blood markers with an impact on health risk assessment, prevention and drug development.
The tests have the potential to significantly improve doctors' possibilities to predict and prevent people from getting ill. The most advanced applications for our tests are for important risk groups such as breast cancer patients, heart attack cases, or diabetes type 2 sufferers. Immunovia AB is headquartered in Lund, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage